Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters

Journal of Urology

Volumn 145, Issue 2, 1991, Pages 313-318

  Chybowski, F M ^a   Keller, J J L ^a   Bergstralh, E J ^a   Oesterling, J E ^a  

^a DEPARTMENT OF UROLOGY   (United States)

Author keywords

Adenocarcinoma; Antigens; Neoplasm; Prostate; Prostatic neoplasms; Radionuclide imaging

Indexed keywords

ACID PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE SCINTISCANNING; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0026092514     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(17)38325-8     Document Type: Article

References (26)

1. Silverberg E. Boring C.C. Squires T.S. Cancer statistics 1990 CA 40 1990 9
2. Catalona W.J. Scott W.W. Carcinoma of the prostate 5th ed P.C. Walsh R.F. Gittes A.D. Perlmutter T.A. Stamey Campbell’s Urology vol. 2 1986 W. B. Saunders Co. Philadelphia 1463 1534 chapt. 32
3. McGregor B. Tulloch A.G.S. Quinlan M.F. Lovegrove F. The role of bone scanning in the assessment of prostatic carcinoma Brit. J. Urol. 50 1978 178
4. O’Donoghue E.P.N. Constable A.R. Sherwood T. Stevenson J.J. Chisholm G.D. Bone scanning and plasma phosphatases in carcinoma of the prostate Brit. J. Urol. 50 1978 172
5. Schaffer D.L. Pendergrass H.P. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate Radiology 121 1976 431
6. Catalona W.J. Prostate Cancer 1984 Harcourt Brace Jovanovich, Publishers Orlando
7. Wahner H.W. Brown M.L. Role of bone scanning F.H. Sim Diagnosis and Management of Metastatic Bone Disease 1988 Raven Press New York 51 67 chapt. 8
8. Utz D.C. Farrow G.M. Pathologic differentiation and prognosis of prostatic carcinoma J.A.M.A. 209 1969 1701
9. Kind P.R.N. King E.J. Estimation and plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine J. Clin. Path. 7 1954 322
10. Rock R.C. Chan D.W. Bruzek D. Waldron C. Oesterling J. Walsh P. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen Clin. Chem. 33 1987 2257
11. Cleary P.D. Bush B.T. Kessler L.G. Evaluating the use of mental health screening scales in primary care settings using receiver operating characteristic curves Medical Care 25 suppl. 1987 S90
12. Donohue R.E. Mani J.H. Whitesel J.A. Mohr S. Scanaviro D. Augspurger R.R. Biber R.J. Fauver H.E. Wettlaufer J.N. Pfister R.R. Pelvic lymph node dissection: guide to patient management in clinically locally confined adenocarcinoma of the prostate Urology 20 1982 559
13. Oesterling J.E. Brendler C.B. Epstein J.I. Kimball A.W. Jr. Walsh P.C. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate J. Urol. 138 1987 92
14. Gleason D.F. Mellinger G.T. The Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J. Urol. 111 1974 58
15. Kramer S.A. Spahr J. Brendler C.B. Glenn J.F. Paulson D.F. Experience with Gleason’s histopathologic grading in prostatic cancer J. Urol. 124 1980 223
16. Smith J.A. Jr. Seaman J.P. Gleidman J.B. Middleton R.G. Pelvic lymph node metastases from prostate cancer: influence of tumor grade and stage in 452 consecutive patients J. Urol. 130 1983 290
17. Gutman A.B. Gutman E.B. An “acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland J. Clin. Invest. 17 1938 473
18. Woodard H.Q. Factors leading to elevations in serum acid glycerophosphatase Cancer 5 1952 236
19. Henneberry M.O. Engel G. Grayhack J.T. Acid phosphatase Urol. Clin. N. Amer. 6 1979 629
20. Wang M.C. Valenzuela L.A. Murphy G.P. Chu T.M. Purification of a human prostate specific antigen Invest. Urol. 17 1979 159
21. Stamey T.A. Yang N. Hay A.R. McNeal J.E. Freiha F.S. Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate New Engl. J. Med. 317 1987 909
22. Hudson M.A. Bahnson R.R. Catalona W.J. Clinical use of prostate specific antigen in patients with prostate cancer J. Urol. 142 1989 1011
23. Lange P.H. Ercole C.J. Lightner D.J. Fraley E.E. Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy J. Urol. 141 1989 873
24. Killian C.S. Emrich L.J. Vargas F.P. Yang N. Wang M.C. Priore R.L. Murphy G.P. Chu T.M. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer J. Natl. Cancer Inst. 76 1986 179
25. Oesterling J.E. Chan D.W. Epstein J.I. Kimball A.W. Jr. Bruzek D.J. Rock R.C. Brendler C.B. Walsh P.C. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy J. Urol. 139 1988 766
26. Zincke, H.: Personal communication.